T-cell receptor therapy in the treatment of ovarian cancer: a mini review
- Journal Title
- Frontiers in Immunology
- Abstract
- Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive and deadly female cancers with limited treatment options. These tumors are generally unresponsive to immune check-point inhibitor (ICI) therapy and are referred to as immunologically "cold" tumors. Cell-based therapy, in particular, adoptive T-cell therapy, is an alternative immunotherapy option that has shown great potential, especially chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies. However, the efficacy of CAR-T therapy in solid tumors has been modest. This review explores the potential of another cell-based therapy, T-cell receptor therapy (TCR-T) as an alternate treatment option for immunological "cold" OC and OCS tumors.
- Publisher
- Frontiers Media
- Keywords
- T-cell receptor; cell-based therapy; immunotherapy; ovarian cancer; tumor neoantigen
- Research Division(s)
- Bioinformatics; Cancer Biology And Stem Cells
- PubMed ID
- 33927729
- Publisher's Version
- https://doi.org/10.3389/fimmu.2021.672502
- Open Access at Publisher's Site
https://doi.org/10.3389/fimmu.2021.672502- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-05-11 04:12:20
Last Modified: 2021-05-17 11:38:28